Diagnostics

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Reinhard Krickl invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Florian Eckhardt is listed in a Senior Advisor capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Nora Kaarela invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Fabrizio Landi.

Fabrizio Landi works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Beverina.

Alessio Beverina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Diana Saraceni.

Diana Saraceni works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Barbara Castellano.

Barbara Castellano works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Rob Woodman.

Rob Woodman works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Marco Sardina.

Marco Sardina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Piuma.

Alessio Piuma works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Andrea Ballerini.

Andrea Ballerini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Giacomo Piccinini.

Giacomo Piccinini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Annalisa Coraducci.

Annalisa Coraducci works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Lorenzo Giordano.

Lorenzo Giordano serves Panakès Partners as Chief Financial Officer. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Paola Crovato.

Paola Crovato serves Panakès Partners as Office and Deal Flow Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Federica Porcu.

Federica Porcu serves Panakès Partners as Financial Controller and ESG Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Michela Barcella.

Michela Barcella serves Panakès Partners as Network and Portfolio Talent Advisor. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Barbora Šumová, Ph.D. invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Tomáš Maršálek, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Dr. Anela Vukoja invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Magdalena Marciniak, Ph.D. is listed in a Advisor capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Pavlína Koutecká invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Simona Šandová is listed in a Office Manager capacity at i&i Bio. The firm does not publish a person-specific investment mandate for this role; the firm's strategy is included only as shared organizational context.

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Gaston Matthyssens, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Alain Parthoens invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Christian Schneider, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Stephane Verdood invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Guy Geldhof invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Rainer Strohmenger invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Johannes Fischer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Varun Gupta invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Harald Keller is listed in a Managing Partner, CFO capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Ernst Mannheimer is listed in a Managing Partner, Legal Counsel capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Sabine Kannegiesser invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Lisa Gartenmann invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Robert Buschauer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Karina Schuster is listed in a Office Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Ulrike Spring is listed in a Sustainability Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Cornelia Huber is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Karin Juen is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Anja Weibel is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Olena Ionkina is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Doris Gowik invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Regina Hodits is listed in a Venture Advisor capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Prof. Dr. Erich Schlick invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Ulrich Granzer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Mel Spigelman invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Wolfgang Baiker invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Stuart Essig, Ph.D. invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Bo Jesper Hansen invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Peter Hirth invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Alain Parthoens is listed in a Chief Executive Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Sadashi Suzuki is listed in a Japan Representative capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Guy Heynen is listed in a Chief Medical and Regulatory Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Michihiko Wada is listed in a Chief Regulatory and Development Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Danny Gonnissen is listed in a Chief Operating Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Pierre Detrixhe invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Tomoko Asaoka invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Dario Padovani is listed in a Chief Financial Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Daisuke Morishita invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Toko Senna is listed in a Assistant to the CEO / Office Manager capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Ajit Shetty is listed in a Chairman of the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Dirk Boogmans is listed in a Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Jean Combalbert is listed in a Independent Director capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Jean-Claude Deschamps is listed in a Chairman Emeritus and Advisor to the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Goro Takeda is listed in a Founder capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Bert-Arjan Millenaar is listed in a Founder & CEO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ruben Mikkers is listed in a CFO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Amalia Stenberg is listed in a Head of Legal, Company Secretary capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Emke Bus is listed in a Head of Investor Relations & Business Development capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ileana Lindeman invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ian Metcalfe invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Nia Emami-Shahri, PhD is listed in a Entrepreneur in Residence capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Augusta Poteliunaite is listed in a Cluster Talent Partner & Recruiter capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Carlos Garcia Tognaccini is listed in a Legal Counsel capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

NLC Health Ventures

Amsterdam, Netherlands

Wellington Partners

Munich, Germany

Kurma Partners

Paris, France / Munich, Germany

Hadean Ventures

Oslo, Norway and Stockholm, Sweden

Newton Biocapital

Brussels, Belgium and Tokyo, Japan

Panakès Partners

Milan, Italy

i&i Bio

Prague, Czechia

Vesalius Biocapital

Luxembourg